SEC Form 4 · accession 0001094891-16-000429
Origo Acquisition Corp · OACQ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Lindsay A Rosenwald M.D.
Officer — Co-Chairman and CEO · Director · 10% Owner
Fortress Biotech, Inc.
10% Owner
Period of report
Feb 3, 2016
Accepted (ET)
Feb 4, 2016 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001619551
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory NoteF3,F4,F1,F2 | $10.00 | Feb 3, 2016 | A | 10,000 | A | — | — | Units | 10,000 | 25,000 | I |
Explanation of responses
- F1The promissory note is convertible, at the Reporting Person's option, at the closing of the Issuer's initial business combination.
- F2Each Unit consists of one ordinary share, one right to receive one-tenth (1/10) of an ordinary share on the consummation of an initial business combination and one redeemable warrant to purchase one-half of one ordinary share at a price of $11.50 per full share, as further described in the Issuer's final prospectus dated December 12, 2014.
- F3The convertible promissory note was issued in consideration of a loan made by the Reporting Person to the Issuer in the amount of $100,000.
- F4Mr. Rosenwald is the Chairman, President and Chief Executive Officer of Fortress Biotech, Inc. (formerly Coronado Biosciences, Inc.), and as such, controls the voting and disposition of such securities. Mr. Rosenwald disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that Mr. Rosenwald is the beneficial owner of these securities for puposes of Section 16 or for any other purpose.